Tissue-specific mtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin
- 1 December 2005
- journal article
- Published by Wiley in The Journal of Pathology
- Vol. 207 (4), 436-444
- https://doi.org/10.1002/path.1863
Abstract
Doxorubicin causes a chronic cardiomyopathy. Although the exact pathogenesis is unknown, recent animal data suggest that somatically acquired alterations of mitochondrial DNA (mtDNA) and concomitant mitochondrial dysfunction play an important role in its onset. In this study, skeletal and myocardial muscles were examined from human autopsies. Compared to controls (n = 8), doxorubicin‐exposed hearts (n = 6) showed low absolute enzyme activity of mtDNA‐encoded nicotinamide adenine dinucleotide hydrogen dehydrogenase (NADH DH, 79% residual activity, p = 0.03) and cytochrome c oxidase (COX, 59% residual activity, p < 0.001), but not of succinate dehydrogenase (SDH), which is encoded exclusively by nuclear DNA. NADH DH/SDH and COX/SDH ratios were 37% (p < 0.001) and 27% (p < 0.001) of controls. Expression of the mtDNA‐encoded subunit II of COX was reduced (82%, p = 0.04), compared to its unchanged nucleus‐encoded subunit IV. MtDNA‐content was diminished (56%, p = 0.02), but the ‘common’ mtDNA‐deletion was increased (9.2‐fold, p = 0.004). Doxorubicin‐exposed hearts harboured numerous additional mtDNA rearrangements lacking direct repeats. They contained elevated levels of malondialdehyde (MDA) (p = 0.006, compared to controls), which correlated inversely with the COX/SDH ratio (r = −0.45, p = 0.02) and the mtDNA‐content (r = −0.75, p = 0.002), and correlated positively with the levels of the ‘common’ deletion (r = 0.80, p < 0.001). Doxorubicin‐exposed hearts also contained the highest levels of superoxide (p < 0.001, compared to controls), which correlated negatively with the mtDNA‐encoded respiratory chain activities, such as the COX/SDH ratio (r = −0.57, p = 0.02) and the NADH/SDH ratio (r = −0.52, p = 0.04), as well as with the mtDNA content (r = −0.69, p = 0.003), and correlated positively with the frequency of the ‘common’ deletion (r = 0.76, p < 0.001) and the MDA levels (r = 0.86, p < 0.001). Doxorubicin‐exposed hearts contained electron‐dense deposits within mitochondria. Hearts exposed to other anthracyclines (n = 6) or skeletal muscle (all groups) had no mitochondrial dysfunction. Doxorubicin, unlike other anthracyclines, augments lipid peroxidation, induces mtDNA mutations and decreases mtDNA content in human hearts. These lesions have an impact on mitochondrial function and could be of importance in the pathogenesis of clinical cardiomyopathy. Copyright © 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 38 references indexed in Scilit:
- Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and CardiotoxicityPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2004
- Mitochondrial DNA replication, nucleoside reverse-transcriptase inhibitors, and AIDS cardiomyopathyProgress in Cardiovascular Diseases, 2003
- Mitochondria and the heartCurrent Opinion in Cardiology, 2001
- Cardiotoxicity of Chemotherapeutic AgentsDrug Safety, 2000
- Cardioselective and cumulative oxidation of mitochondrial DNA following subchronic doxorubicin administrationBiochimica et Biophysica Acta (BBA) - Bioenergetics, 1999
- EpirubicinDrugs, 1993
- Doxorubicin (adriamycin): A critical review of free radical-dependent mechanisms of cytotoxicityPharmacology & Therapeutics, 1990
- DECLINE IN SKELETAL MUSCLE MITOCHONDRIAL RESPIRATORY CHAIN FUNCTION: POSSIBLE FACTOR IN AGEINGThe Lancet, 1989
- Demonstration of the existence of an organo‐specific NADH dehydrogenase in heart mitochondriaEuropean Journal of Biochemistry, 1987
- Sequence and organization of the human mitochondrial genomeNature, 1981